

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TWI PHARMACEUTICALS INC.,

Petitioner,

v.

MERCK SERONO SA,

Patent Owner.

IPR2023-00049 (Patent 7,713,947 B2)

Before ULRIKE W. JENKS, ZHENYU YANG and TINA HULSE,
Administrative Patent Judges.

JENKS, *Administrative Patent Judge.*

PETITIONER'S OPPOSITION TO MOTION TO SEAL

TABLE OF CONTENTS

	Page
TABLE OF CONTENTS	i
TABLE OF AUTHORITIES	ii
EXHIBIT LIST	iii
I. Introduction	1
II. Statement of Material Facts	1
III. Legal Standard	3
IV. Relief Requested – Patent Owner’s Motion Should Be Denied	5
A. Exhibit 2048	5
B. Exhibits 2049 and 2050	9
C. Exhibit 2039	12
V. Motion for Entry of the Default Protective Order	12
VI. Conclusion	12

TABLE OF AUTHORITIES

Page(s)

Cases

<i>Argentum Pharms. LLC v. Alcon Rsch., Ltd.</i> , No. IPR2017-01053, 2018 WL 495204 (P.T.A.B. Jan. 19, 2018)	passim
<i>Corning Optical Communications RF, LLC, v. PPC Broadband, Inc.</i> , No. IPR2014-00440, 2015 WL 1523712 (P.T.A.B. Apr. 6, 2015)	4, 6
<i>Garmin International, Inc. et al. v. Cuozzo Speed Technologies LLC</i> , No. IPR2012-00001, 2013 WL 8696523 (P.T.A.B. March 14, 2013)	3, 4
<i>Skechers U.S.A., Inc. v. Nike, Inc.</i> , No. IPR2017-00620, 2017 WL 4277684 (P.T.A.B. Sept. 25, 2017).....	8, 9, 11
<i>Westinghouse Air Brake Techs. Corp. v. Siemens Mobility, Inc.</i> , Nos. IPR2017-01669, IPR2017-02044, Paper 60 (P.T.A.B. Jan. 8, 2019)	6, 7

Statutes

35 U.S.C. § 316(a)	3
--------------------------	---

Regulations

37 C.F.R. § 42.14	3
37 C.F.R. § 42.54(a)	4

Other Authorities

<i>Patent Trial and Appeal Board Consolidated Trial Practice Guide</i> (November 21, 2019)	3
---	---

EXHIBIT LIST

EXHIBIT	DESCRIPTION	SHORT
Ex. 1001	US 7,713,947 B2.	'947 Patent
Ex. 1002	US 8,377,903 B2.	'903 Patent
Ex. 1003	File History for Ser. No. 11/722,018, which issued as the '947 patent.	'018 File Wrapper
Ex. 1004	File History Ser. No. 12/766,173, which issued as the '903 patent.	'173 File Wrapper
Ex. 1005	Declaration of Dr. Benjamin M. Greenberg, M.D.	Greenberg Decl.
Ex. 1006	<i>Curriculum Vitae</i> of Dr. Benjamin M. Greenberg, M.D.	Greenberg CV
Ex. 1007	WO 2004/087101 A2.	Bodor 'WO 101
Ex. 1008	Rice, George P.A., Massimo Filippi, and Giancarlo Comi. "Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial." <i>Neurology</i> Vol. 54, no. 5 (2000) pp. 1145–1155.	Rice 2000 or Rice
Ex. 1009	Liliemark, Jan. "The clinical pharmacokinetics of cladribine." <i>Clinical pharmacokinetics</i> Vol. 32, no. 2 (1997) pp. 120–131.	Liliemark 1997
Ex. 1010	<i>Merck KGaA et al v. Accord Healthcare, Inc. et al</i> 1-22-cv-00974 (DDE) Complaint.	Merck Complaint
Ex. 1011	EMD Serano Inc., Mavenclad® (Cladribine) Package Insert, Mar. 2019	Mavenclad Package Insert
Ex. 1012	Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. <i>Neurology</i> 1996;46:907–911.	Lublin 1996
Ex. 1013	National Multiple Sclerosis Society, <i>What is MS, Types of MS</i> , https://www.nationalmssociety.org/What-is-MS/Types-of-MS , retrieved Sept. 20, 2022.	
Ex. 1014	National Multiple Sclerosis Society, <i>What is MS, Types of MS, Secondary Progressive MS</i> , https://www.nationalmssociety.org/What-is-	

EXHIBIT	DESCRIPTION	SHORT
	MS/Types-of-MS/Secondary-progressive-MS.	
Ex. 1015	Casanova, B., et al. "High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study," <i>Multiple Sclerosis Journal</i> , Feb. 2002, pp. 59-63, vol. 8.	Casanova 2002
Ex. 1016	Romine, J. et al. "A Double-Blind, Placebo-Controlled, Randomized Trial of Cladribine in Relapsing-Remitting Multiple Sclerosis," <i>Proceedings of the Association of American Physicians</i> , Jan./Feb. 1999, pp. 35-44, vol. 111, No. 1.	Romine 1999
Ex. 1017	Immunex Corporation, Novantrone [®] (Moxantrone) Package Insert, Oct. 13, 2000 ("Novantrone [®] Package Insert").	Novantrone Package Insert
Ex. 1018	Langtry, H. et al. "Cladribine: A Review of its Use in Multiple Sclerosis," <i>Biodrugs</i> , May 1998, pp. 419-433, vol. 9, No. 3.	Langtry 1998
Ex. 1019	Biogen Idec Inc., Tysabri [®] (natalizumab) Package Insert, Nov. 2004.	Tysabri Package Insert
Ex. 1020	Chiron Corporation, Betaseron [®] (Interferon beta-1b) Package Insert, 1993.	Betaseron Package Insert
Ex. 1021	Biogen, Inc., Avonex [™] (Interferon Beta-1a) Package Insert, Nov. 1996.	Avonex Package Insert
Ex. 1022	Teva Pharms USA, Copaxone [®] (glatiramer acetate for injection) Package Insert, 2001.	Copaxone Package Insert
Ex. 1023	Serano, Inc., Rebif [®] (Interferon Beta-1a) Package Insert, May 2003.	Rebif Package Insert
Ex. 1024	Cursiefen, Simone, <i>et al.</i> "Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis," <i>European neurology</i> , Apr. 2000, pp. 186-187, vol. 43, No. 3.	Cursiefen 2000
Ex. 1025	Burt, Richard K., <i>et al.</i> "Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation," <i>Blood, The Journal of the American Society of Hematology</i> , Nov. 1998, pp. 3505-3514, vol. 92, No. 10.	Burt 1998

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.